123 Matching Annotations
  1. Apr 2022
    1. Hilda Bastian, PhD. (2021, February 6). Unofficial unnamed AstraZeneca insider says they are doing the interim analysis for the US trial of the Oxford vaccine. AstraZeneca spokesperson says 4-6 weeks till data release. Https://t.co/VUHgbHN02d One is wrong? Or they’ll release only when have FDA minimum follow-up? Https://t.co/LgjfX8AIti [Tweet]. @hildabast. https://twitter.com/hildabast/status/1357862227106095105

    1. John Lichfield. (2021, April 10). Weekly French vaccination thread. The French roll-out, still described as “stuttering” or “glacial” in UK media (and even some Fr media) continues to boom. Over 500,000 doses (1st/ 2nd) were given yesterday, a record. Fr should exceed its 10m 1st jabs 15 April target by 2m. 1/12 https://t.co/hhJa8rafCV [Tweet]. @john_lichfield. https://twitter.com/john_lichfield/status/1380807805960130561

    1. Michael Bang Petersen. (2021, March 17). This is worsened as costs of #covid19 are not mentally similar to costs of side effects, even if the latter are less risky. People prefer controllable risks to uncontrollabe risks, even if less lethal (https://t.co/kSIcObWYmT). That is why you fear flying but not driving. [2/2] [Tweet]. @M_B_Petersen. https://twitter.com/M_B_Petersen/status/1372103708218159109

  2. Mar 2022
  3. Feb 2022
    1. Jonathan Li on Twitter: “There’s a lineage of Omicron that’s gained the R346K mutation (BA.1.1). This one could spell some trouble for the AZ mAb (tixagevimab/cilgavimab, Evusheld) that’s being used for pre-exposure prophylaxis. If you want to learn about tix/cil vs Omicron, read on 1/7” / Twitter. (n.d.). Retrieved February 6, 2022, from https://twitter.com/DrJLi/status/1487479972293853188

  4. Dec 2021
    1. ReconfigBehSci. (2021, December 13). RT @DrEricDing: 11) Omicron is doubling every 1.6 days in UK 🇬🇧 according to @DrWilliamKu’s figure. That’s way faster growth than in South… [Tweet]. @SciBeh. https://twitter.com/SciBeh/status/1470451594378502154

    1. Munro, A. P. S., Janani, L., Cornelius, V., Aley, P. K., Babbage, G., Baxter, D., Bula, M., Cathie, K., Chatterjee, K., Dodd, K., Enever, Y., Gokani, K., Goodman, A. L., Green, C. A., Harndahl, L., Haughney, J., Hicks, A., van der Klaauw, A. A., Kwok, J., … Appleby, K. (2021). Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): A blinded, multicentre, randomised, controlled, phase 2 trial. The Lancet, S0140673621027173. https://doi.org/10.1016/S0140-6736(21)02717-3 s

  5. Nov 2021
  6. Oct 2021
    1. Pozzetto, B., Legros, V., Djebali, S., Barateau, V., Guibert, N., Villard, M., Peyrot, L., Allatif, O., Fassier, J.-B., Massardier-Pilonchéry, A., Brengel-Pesce, K., Yaugel-Novoa, M., Denolly, S., Boson, B., Bourlet, T., Bal, A., Valette, M., Andrieu, T., Lina, B., … Trouillet-Assant, S. (2021). Immunogenicity and efficacy of heterologous ChadOx1/BNT162b2 vaccination. Nature, 1–9. https://doi.org/10.1038/s41586-021-04120-y

    1. Hulme, W. J., Williamson, E. J., Green, A., Bhaskaran, K., McDonald, H. I., Rentsch, C. T., Schultze, A., Tazare, J., Curtis, H. J., Walker, A. J., Tomlinson, L., Palmer, T., Horne, E., MacKenna, B., Morton, C. E., Mehrkar, A., Fisher, L., Bacon, S., Evans, D., … Goldacre, B. (2021). Comparative effectiveness of ChAdOx1 versus BNT162b2 COVID-19 vaccines in Health and Social Care workers in England: A cohort study using OpenSAFELY [Preprint]. Epidemiology. https://doi.org/10.1101/2021.10.13.21264937

    1. Barros-Martins, J., Hammerschmidt, S. I., Cossmann, A., Odak, I., Stankov, M. V., Morillas Ramos, G., Dopfer-Jablonka, A., Heidemann, A., Ritter, C., Friedrichsen, M., Schultze-Florey, C., Ravens, I., Willenzon, S., Bubke, A., Ristenpart, J., Janssen, A., Ssebyatika, G., Bernhardt, G., Münch, J., … Behrens, G. M. N. (2021). Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nature Medicine, 1–5. https://doi.org/10.1038/s41591-021-01449-9

  7. Aug 2021
  8. Jul 2021
    1. CitiNewsroom. (2021, July 15). The AstraZeneca Africa Director, Barbara Nel, has disclosed that a total of 1.6 billion fully funded COVID-19 vaccines would be made available for COVAX dependent countries later this year through to 2022. | Watch the full interview with @benkoku here: Https://t.co/kw3BKzMclU https://t.co/6gQ1DZMnB6 [Tweet]. @Citi973. https://twitter.com/Citi973/status/1415697599236018181

  9. Jun 2021
    1. Michael Makris on Twitter: “The cumulative incidence of VITT after AZ first vaccination in the UK is continuing to increase with the latest data being 1 in 81,000. However this is rather misleading because VITT is age related with a higher incidence in the young. Https://t.co/CSjshAoRsN” / Twitter. (n.d.). Retrieved June 27, 2021, from https://twitter.com/ProfMakris/status/1395457748721184777?s=20

    1. Pritchard, E., Matthews, P. C., Stoesser, N., Eyre, D. W., Gethings, O., Vihta, K.-D., Jones, J., House, T., VanSteenHouse, H., Bell, I., Bell, J. I., Newton, J. N., Farrar, J., Diamond, I., Rourke, E., Studley, R., Crook, D., Peto, T. E. A., Walker, A. S., & Pouwels, K. B. (2021). Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. Nature Medicine, 1–9. https://doi.org/10.1038/s41591-021-01410-w

  10. May 2021
  11. Apr 2021